scholarly journals HIỆU QUẢ THUỐC SULPIRIDE TRONG CẢI THIỆN CHẤT LƯỢNG CUỘC SỐNG Ở BỆNH NHẬN HỘI CHỨNG RUỘT KÍCH THÍCH

2021 ◽  
Vol 502 (1) ◽  
Author(s):  
Võ Duy Thông ◽  
Nguyễn Ngọc Phúc
Keyword(s):  
Rome Iii

Đặt vấn đề: Hội chứng ruột kích thích (IBS) là một bệnh lý với các triệu chứng đường tiêu hóa như đau bụng, chướng bụng, đầy hơi, ảnh hưởng nhiều đến chất lượng cuộc sống (CLCS) của bệnh nhân (BN). Mục tiêu: Khảo sát hiệu quả điều trị của thuốc sulpiride trong cải thiện chất lượng cuộc sống ở bệnh nhận hội chứng ruột kích thích. Đối tượng và phương pháp nghiên cứu: Nghiên cứu cắt ngang mô tả thực hiện trên những BN IBS được bác sĩ chẩn đoán bằng tiêu chuẩn ROME III tại phòng khám Tiêu hoá, bệnh viện Đại học Y Dược TP. Hồ Chí Minh từ 01/06/2018 – 01/02/2019, có hoặc không sử dụng sulpiride. Thu thập số liệu về đặc điểm nền của bệnh nhân, điểm CLCS được thu thập dựa trên bộ câu hỏi IBS-QoL phiên bản tiếng Việt đã được dịch thuật và thẩm định cho toàn bộ đối tượng tham gia nghiên cứu tại thời điểm ban đầu và sau 8 tuần theo dõi. Kết quả: Sau 8 tuần theo dõi, 246 BN hoàn thành nghiên cứu, trong đó 120 BN nhóm điều trị có sulpiride và 126 BN nhóm điều trị không có sulpiride, tỷ lệ nữ/nam là 1,4/1. Sau 8 tuần theo dõi, kết quả điểm CLCS tổng thể và các điểm CLCS ở các khía cạnh đặc điểm khó chịu, lo lắng sức khỏe, phản ứng xã hội, mối quan hệ cao hơn có ý nghĩa thống kê so với nhóm không sulpiride (p < 0,001). Khi đánh giá độ thay đổi điểm CLCS, độ thay đổi điểm CLCS tổng thể và các khía cạnh khó chịu, cản trở hoạt động, hình thể, lo lắng sức khỏe, phản ứng xã hội, mối quan hệ ở nhóm có sulpiride cũng cao hơn có ý nghĩa thống kê so với nhóm không dùng sulpiride, ulpuride (p < 0,05). Kết luận: Sử dụng thuốc sulpiride điều trị BN IBS giúp cải thiện CLCS tổng thể, thay đổi ở các đặc điểm khó chịu, cản trở hoạt động, hình thể, lo lắng sức khỏe, phản ứng xã hội, mối quan hệ.

Symptomatic Treatment of Pain-Related Pediatric Functional Gastrointestinal Disorders in a Biopsychosocial Construct, and a Validity Study of Rome III Criteria

2021 ◽  
Vol 60 (6-7) ◽  
pp. 304-313
Author(s):  
Shailender Madani ◽  
Rohit Madani ◽  
Suchi Parikh ◽  
Ahila Manivannan ◽  
Wilma R. Orellana ◽  
...  
Keyword(s):  
Positive Predictive Value ◽  
Predictive Value ◽  
Functional Gastrointestinal Disorders ◽  
High Specificity ◽  
Symptomatic Treatment ◽  
Gastrointestinal Disorders ◽  
Organic Disease ◽  
Rome Iii Criteria ◽  
Rome Criteria ◽  
Rome Iii

Our study aims to assess improvement with symptomatic treatment of pain-related functional gastrointestinal disorders (FGIDs) in a biopsychosocial construct and evaluate validity of Rome III criteria. Children with chronic abdominal pain diagnosed with an FGID or organic disease were followed for 1 year: 256/334 were diagnosed with an FGID and 78/334 were diagnosed with a possible organic disease due to alarm signs or not meeting Rome III criteria. After 1 year, 251 had true FGID and 46 had organic diseases. Ninety percent of FGID patients improved with symptomatic treatment over an average of 5.4 months. With a 95% confidence interval, Rome criteria predicted FGIDs with sensitivity 0.89, specificity 0.90, positive predictive value 0.98, and negative predictive value 0.59. We conclude that symptomatic treatment of pain-related FGIDs results in clinical improvement and could reduce invasive/expensive testing. Rome III criteria’s high specificity and positive predictive value suggest they can rule in a diagnosis of FGID.

scholarly journals Functional gastrointestinal disorders in children: agreement between Rome III and Rome IV diagnoses

2021 ◽  
Author(s):  
Desiree F. Baaleman ◽  
Carlos A. Velasco-Benítez ◽  
Laura M. Méndez-Guzmán ◽  
Marc A. Benninga ◽  
Miguel Saps
Keyword(s):  
Diagnostic Criteria ◽  
Functional Dyspepsia ◽  
Functional Gastrointestinal Disorders ◽  
Functional Constipation ◽  
Final Analysis ◽  
Gastrointestinal Disorders ◽  
Rome Iii ◽  
Sample Characteristics ◽  
Irritable Bowel ◽  
Rome Iv

AbstractTo evaluate the agreement between the Rome III and Rome IV criteria in diagnosing pediatric functional gastrointestinal disorders (FGIDs), we conducted a prospective cohort study in a public school in Cali, Colombia. Children and adolescents between 11 and 18 years of age were given the Spanish version of the Questionnaire on Pediatric Functional Gastrointestinal Disorders Rome III version on day 0 and Rome IV version on day 2 (48 h later). The study protocol was completed by 135 children. Thirty-nine (28.9%) children were excluded because of not following the instructions of the questionnaire. The final analysis included data of 96 children (mean 15.2 years old, SD ± 1.7, 54% girls). Less children fulfilled the criteria for an FGID according to Rome IV compared to Rome III (40.6% vs 29.2%, p=0.063) resulting in a minimal agreement between the two criteria in diagnosing an FGID (kappa 0.34, agreement of 70%). The prevalence of functional constipation according to Rome IV was significantly lower compared to Rome III (13.5% vs 31.3%, p<0.001), whereas functional dyspepsia had a higher prevalence according to Rome IV than Rome III (11.5% vs 0%).Conclusion: We found an overall minimal agreement in diagnosing FGIDs according to Rome III and Rome IV criteria. This may be partly explained by the differences in diagnostic criteria. However, limitations with the use of questionnaires to measure prevalence have to be taken into account. What is Known:• The Rome IV criteria replaced the previous Rome III criteria providing updated criteria to diagnose functional gastrointestinal disorders (FGIDs).• Differences found between Rome IV and historic Rome III FGID prevalence may have been affected by changes in prevalence over time or differences in sample characteristics. What is New:• We found a minimal agreement between Rome III and Rome IV FGID diagnosis, especially in the diagnoses of functional constipation, irritable bowel syndrome, and functional dyspepsia.• The minimal agreement may be partly explained by changes in diagnostic criteria, but limitations with the use of questionnaires to measure prevalence have to be taken into account.

scholarly journals Serotonin-Related Gene Variants in Patients with Irritable Bowel Syndrome and Depressive or Anxiety Disorders

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Magdalena Grzesiak ◽  
Jan Aleksander Beszłej ◽  
Ewa Waszczuk ◽  
Marcin Szechiński ◽  
Monika Szewczuk-Bogusławska ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Anxiety Disorders ◽  
Depressive Disorders ◽  
Composite International Diagnostic Interview ◽  
Diagnostic Interview ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide ◽  
New Findings ◽  
Rome Iii ◽  
Irritable Bowel

Aim. To assess the association of six polymorphisms in serotonin-related genes with depressive or anxiety disorders in patients with irritable bowel syndrome (IBS).Methods. The lifetime prevalence of depressive and anxiety disorders was assessed in 95 IBS patients (85% women) using the Munich version of the Composite International Diagnostic Interview (CIDI). IBS was diagnosed according to the Rome III criteria.SCL6A4HTTLPR polymorphism (rs4795541) was determined using PCR-based method. Single-nucleotide polymorphisms inHTR1A(rs6295),HTR2A(rs6313 and rs6311),HTR2C(rs6318), andTPH1(rs1800532) were detected by minisequencing method.Results. IBS patients with depressive disorders were characterized by higher frequency of 5-HTTLPR L allele in comparison to IBS patients with anxiety disorders. The lower frequency of 1438 A allele inHTR2Awas found in IBS patients with depressive disorders in comparison to IBS patients without mental disorders. The lower G allele frequency inHTR2Crs6318 polymorphism among IBS patients with anxiety disorders was also observed.Conclusions. Our results provide further evidence for the involvement ofSLC6A4rs4795541 andHTR2Ars6311 polymorphisms in the pathophysiology of depressive disorders in IBS patients. The new findings indicate thatHTR2Crs6318 polymorphism may be associated with the susceptibility to anxiety disorders in IBS patients.

scholarly journals Laxative co-medication and changes in defecation patterns during opioid use

2018 ◽  
Vol 25 (7) ◽  
pp. 1613-1621
Author(s):  
Frans de Bruin ◽  
Karin Hek ◽  
Jan van Lieshout ◽  
Monique Verduijn ◽  
Pim Langendijk ◽  
...  
Keyword(s):  
Hospital Admissions ◽  
Functional Gastrointestinal Disorders ◽  
Community Pharmacists ◽  
Opioid Use ◽  
Chi Square ◽  
Rome Iii ◽  
Stool Form ◽  
Waiting Strategy ◽  
Watchful Waiting Strategy ◽  
Opioid Users

Introduction Opioid-induced constipation is a clinically relevant side effect and a cause of potentially avoidable drug-related hospital admissions. Objectives To describe the presence of laxative co-medication, the reasons for not starting laxatives and to evaluate changes in stool patterns of opioid initiators. Methods In this observational study community pharmacists evaluated the availability of laxative co-medication in starting opioid users and registered reasons for non-use. Two opioid initiators per pharmacy were invited to complete questionnaires (‘Bristol stool form scale’ and ‘Rome III Diagnostic Questionnaire for the Adult Functional Gastrointestinal Disorders’) on their defecation prior to and during opioid use. Descriptive statistics and Chi square tests were used to analyse reasons for non-use of laxatives and changes in defecation patterns. Results Eighty-one pharmacists collected data from 460 opioid initiators. Of those, 344 (74.8%) used laxatives concomitantly. Main reason not to use laxatives was that either prescribers or patients did not consider them necessary. Sixty-seven (89.3%) of the 75 opioid starters with two questionnaires completed were not constipated at opioid start. Eleven of them (16%) developed constipation during opioid use (Chi square p=0.003). At follow-up within laxative users 10.6% were constipated compared to 20.7% in subjects without laxatives. Conclusion One in four opioid starters did not dispose of laxative co-medication, mainly because they were not considered necessary by either the prescriber or the patient. The prevalence of constipation doubled during opioid use. A watchful waiting strategy for the use of laxative co-medication might include a monitoring of defecation patterns with validated questionnaires.

Sign in / Sign up

Export Citation Format

Share Document